Pharmaceutical company Cipla to scale up Remdesivir production 2-fold

The drug remdesivir appears to help treat those suffering from COVID-19, the disease caused by the novel coronavirus

Pharmaceutical company Cipla on Tuesday said it has scaled up the production of remdesivir by 2 times from the last wave of the pandemic.

As the demand for the drug surges, the government has prohibited the exports of remdesivir injection and its active pharmaceutical ingredients (API).

“Given the unprecedented demand for the drug, we have now further ramped up our capacities through our network, to service the demand,” the company said in a statement.

“To ensure fair and equitable access, we are working with the regulatory authorities to restrict supply of the drug only to hospital channels and especially those regions with high burden of severe Covid-19,” Cipla said.

On Tocilizumab, the company said that given the spike in cases and surge in demand, it is facing a shortage and working closely with its partner in taking necessary steps to ensure availability of the drug.

“We expect intermittent supplies as the demand outstrips supply with some more receipts at the earliest,” it added.

Previous articleFlorida to close wastewater reservoir with leak history
Next articleMedvedev tests positive for COVID-19, out of Monte Carlo Masters
Arushi Sana is the Co Founder of NYK Daily. She was a Forensic Data Analyst previously employed with EY (Ernst & Young). She aims to develop a global community of knowledge and journalism par excellence through this News Platform. Arushi holds a degree in Computer Science Engineering. She is also a Mentor for women suffering from Mental Health, and helps them in becoming published authors. Helping and educating people always came naturally to Arushi. She is a writer, political researcher, a social worker and a singer with a flair for languages. Travel and nature are the biggest spiritual getaways for her. She believes Yoga and communication can make the world a better place, and is optimistic of a bright yet mysterious future!

Was it worth reading? Let us know.